ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. ERRs (degludec/glargine U100) of hypoglycemia.

Slides:

Advertisements

Similar presentations

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Advertisements

Canadian Diabetes Association Clinical Practice Guidelines Management of Stroke in Diabetes Chapter 27 Michael Sharma, Gord Gubitz.

Follow Up Questions Diabetes is caused by an increase in blood glucose. People with diabetes II also have a very high risk for developing Alzheimer’s disease.

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

Copyright © 2015 by the American Osteopathic Association.

Using Hemoglobin A1c to Derive Mean Blood Glucose in Peritoneal Dialysis Patients Am J Nephrol 2013;37: DOI: / Fig. 1. Comparison.

From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.

Volume 70, Issue 8, Pages (October 2006)

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Modern Advances in Glucose Monitoring

Selected efficacy and safety parameters.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.

Change in random blood glucose level, body weight, and intraperitoneal glucose tolerance test (IPGTT) in streptozotocin (STZ)-induced diabetic mice. Change.

Time-course changes in blood glucose (BG; A), C peptide (B), and non-esterified fatty acid (NEFA; C) levels. Time-course changes in blood glucose (BG;

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development.

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

Blood glucose readings over time, with superimposed LOESS trend lines.

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.

Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Flow chart of patients who met inclusion/exclusion criteria in the identified study population.1 Excluded because they were living in nursing facility.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Selection of DFU patients and non-DFU controls

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

This figure illustrates the importance of heart failure consideration in primary endpoint trials with hypoglycemic agents. This figure illustrates the.

Blood glucose levels in chicken embryos.

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Time course of HbA1c (A), FPG (B), body weight (C), SMPG (D), and lipase (E) from week 0 to week 26. Time course of HbA1c (A), FPG (B), body weight (C),

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Distribution of daily frequency of BGM

Effects of d-xylose or sucralose (control) with or without sitagliptin on gastric emptying (half-emptying time [T50]) (n = 12). Effects of d-xylose or.

The continuous line represents the sensor glucose values.

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Initiation and adjustment of insulin regimens.

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,

Postoperative blood glucose levels and total insulin requirement.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

The risk for incident cognitive dysfunction after an episode of severe (A) or nonsevere (B) hypoglycemia with and without accounting for the competing.

Elevated blood glucose vs time.

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Association of objective and self-reported PA measurements and VAT mass. Association of objective and self-reported PA measurements and VAT mass. Linear.

Benchmarking scatterplot for non-ICU units.

Presentation transcript:

ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Full analysis set. *Only four episodes of severe hypoglycemia were reported in the maintenance period, which precluded statistical analysis. P values derived using a Poisson Model with logarithm of the exposure time (100 years) as offset; estimates adjusted for treatment, period, sequence, and dosing time as fixed effects and patient as random effects. BG, blood glucose. Louis Chaykin et al. Clin Diabetes 2019;37:73-81 ©2019 by American Diabetes Association